CureVac N.V.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CureVac N.V. is a global biopharmaceutical company headquartered in Tübingen, Germany, specializing in developing transformative medicines based on messenger RNA (mRNA) technology. Founded in 2000, CureVac focuses on the discovery, development, manufacturing, and commercialization of mRNA-based prophylactic vaccines and therapeutic candidates. Its product portfolio includes clinical and preclinical candidates targeting infectious diseases such as COVID-19, seasonal influenza, and urinary tract infections; oncology vaccine candidates including off-the-shelf and personalized cancer immunotherapies; and molecular therapies that utilize optimized mRNAs for therapeutic protein production. Notably, CureVac provides "The RNA Printer," an automated platform for mRNA therapeutic manufacturing. The company's technology leverages a proprietary second-generation mRNA backbone and lipid nanoparticle delivery systems through partnerships such as Acuitas Therapeutics. Recent major developments include the restructuring of the collaboration with GlaxoSmithKline (GSK) into a new licensing agreement in 2024, under which GSK has assumed full rights to develop, manufacture, and globally commercialize CureVac's mRNA vaccine candidates for influenza and COVID-19, including combination vaccines. This deal provided CureVac with upfront and milestone payments totaling up to €1.45 billion, along with high single to low teen royalties while allowing CureVac to retain rights to undisclosed infectious disease targets. CureVac is advancing its oncology pipeline through a strategic collaboration with MD Anderson Cancer Center to develop novel mRNA-based off-the-shelf cancer vaccines for hematological and solid tumors. Additionally, it is progressing a new precision immunotherapy program targeting squamous non-small cell lung cancer (sqNSCLC) with an FDA-cleared Phase 1 study initiated in 2025. CureVac continues to innovate in preclinical and clinical mRNA vaccine and therapeutic candidates while maintaining a strong financial position to support ongoing R&D efforts worldwide across Europe, the U.S., and other regions. CureVac operates primarily within the biotechnology and pharmaceutical industries, developing products for infectious diseases, oncology, and molecular therapies. Its target markets comprise global populations at risk for infectious diseases, cancer patients with significant unmet medical needs, and pharmaceutical partners leveraging its mRNA platform technology. CureVac's operations are amplified through strategic alliances including GSK, MD Anderson, CRISPR Therapeutics, and myNEO Therapeutics, advancing its capabilities in vaccine development, gene editing therapeutics, and AI-driven tumor antigen identification. Overall, CureVac presents as an innovator in the mRNA space, with a comprehensive product pipeline addressing prophylactic vaccines and therapeutic candidates, and a strategic shift toward profitable partnerships and oncology product development marking its latest corporate evolution. The company sustains its biopharmaceutical mission through cutting-edge technology platforms and global clinical development activities, anchored by its German headquarters and multiple international collaborations.
CureVac sues Moderna for patent infringement over COVID-19 vaccines
CureVac N.V. (NASDAQ:CVAC) Given Consensus Recommendation of “Hold” by Analysts
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript
CureVac Announces Voting Results of Extraordinary General Meeting
Brokerages Set CureVac N.V. (NASDAQ:CVAC) PT at $6.83
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
CureVac: The Hidden Value Of The mRNA Wallet
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac Announces Voting Results of General Meeting
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
CureVac Stock Soars on BioNTech Buyout
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders